
    
      A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to
      Evaluate Efficacy and Safety of Saxagliptin in Combination with Metformin and Sulfonylurea in
      Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control with Combination of
      Metformin and Sulfonylurea
    
  